Evidence map›Paper›PMID 36110513›Full record

SynthesisFrontiers in pharmacology2022

Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.

Pu Ge, Ning Wan, Xiao Han, Xinpei Wang, Jinzi Zhang, Xiaoyi Long, Xiaonan Wang, Ying Bian

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Colorectal cancer: Recent advances in management and treatment.World journal of clinical oncology · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Pu GeInstitute of Chinese Medical Sciences, University of Macau, Macau, China.
Ning WanGeneral Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Xiao HanSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Xinpei WangInstitute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
Jinzi ZhangCollege of Humanities and Social Sciences, Harbin Medical University, Harbin, China.
Xiaoyi LongThe First Affiliated Hospital of Medical School of Zhejiang, Hangzhou, China.
Xiaonan WangSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Ying BianInstitute of Chinese Medical Sciences, University of Macau, Macau, China.
University of Macau · MOChina Pharmaceutical University · CNFirst Affiliated Hospital Zhejiang University · CNGeneral Hospital of Guangzhou Military Command · CNHarbin Medical University · CNSun Yat-sen University · CNUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

afliberceptcost-effectiveness analysismetastatic colorectal cancerpharmacoeconomicsrapid health technology assessmenttargeted drugs

Identifiers

PMID36110513
PMCPMC9469875
OpenAlexW4293582013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.